Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Brigitte Neuber"'
Autor:
Anita Schmitt, Brigitte Neuber, Michael Schmitt, Melanie Märklin, Boris Klimovich, Claudia Lengerke, Emmanuelle Moraes Ribeiro, Kathy-Ann Secker, Ana-Maria Nitulescu, Rebekka Schairer, Hildegard Keppeler, Anton Wesle, Hannes Schmid, Daniela Chmiest, Silvia Podavini, Fulya Korkmaz, Corina Schneidawind, Dominik Schneidawind
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Relapse and graft-versus-host disease (GVHD) are the main causes of death after allogeneic hematopoietic cell transplantation (HCT). Preclinical murine models and clinical data suggest that invariant natural killer T (iNKT) cells prevent a
Externí odkaz:
https://doaj.org/article/2907d4c839b94d97ad13f309c1992704
Autor:
Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp-Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs, Andreas Kulozik, Joachim Kunz, Petra Pavel, Sascha Laier, Patrick Wuchter, Johann Schmier, Gesine Bug, Fabian Lang, Nicola Gökbuget, Jochen Casper, Martin Görner, Jürgen Finke, Andreas Neubauer, Mark Ringhoffer, Denise Wolleschak, Monika Brüggemann, Simon Haas, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-17 (2023)
Abstract Background Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 invest
Externí odkaz:
https://doaj.org/article/26e8df351a78481d84b79ca3e21d57c8
Autor:
Genqiao Jiang, Brigitte Neuber, Angela Hückelhoven-Krauss, Uta E. Höpken, Yuntian Ding, David Sedloev, Lei Wang, Avinoam Reichman, Franziska Eberhardt, Martin Wermke, Armin Rehm, Carsten Müller-Tidow, Anita Schmitt, Michael Schmitt
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 3, p 1394 (2024)
The search for target antigens for CAR-T cell therapy against multiple myeloma defined the B-cell maturation antigen (BCMA) as an interesting candidate. Several studies with BCMA-directed CAR-T cell therapy showed promising results. Second-generation
Externí odkaz:
https://doaj.org/article/77390e923e834f6c93e884ad136faca6
Autor:
Lei Wang, Arianeb Mehrabi, Maria-Luisa Schubert, Anita Schmitt, Brigitte Neuber, Alexander Kunz, Angela Hückelhoven-Krauss, Carsten Müller-Tidow, Michael Schmitt, Christian Morath, Martin Zeier, Constantin Schwab, Anja Sander, Sabine Scherer, Claudius Speer, Christian Kleist, Claudia Sommerer, Florian Kälble, Christian Nusshag, Matthias Schaier, Louise Benning, Vedat Schwenger, Caner Süsal, Gerhard Opelz, T. Hien Tran, Stephan Kemmner, Michael Fischereder, Manfred Stangl, Ingeborg A. Hauser, Christian Bischofs, Sandra Sauer, Rüdiger Waldherr, Christopher Büsch, David Czock, Georg A Böhmig, Jochen Reiser, Axel Roers, Peter Terness, Volker Daniel
Publikováno v:
BMJ Open, Vol 12, Iss 11 (2022)
Introduction Donor-derived modified immune cells (MIC) induced long-term specific immunosuppression against the allogeneic donor in preclinical models of transplantation. In a phase I clinical trial (TOL-1 Study), MIC treatment resulted in a cellular
Externí odkaz:
https://doaj.org/article/6362680b60bd43139a9d0cb0059a65b3
Autor:
Yibin Liu, Anna Keib, Brigitte Neuber, Lei Wang, Angelika B. Riemer, Maria Bonsack, Angela Hückelhoven-Krauss, Anita Schmitt, Carsten Müller-Tidow, Michael Schmitt
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 3, p 1943 (2023)
The transcription factor SOX11 is a tumor-associated antigen with low expression in normal cells, but overexpression in glioblastoma (GBM). So far, conventional surgery, chemotherapy, and radiotherapy have not substantially improved the dismal progno
Externí odkaz:
https://doaj.org/article/b9bc6f61c32e43db8f7e5a5be48aa209
Autor:
Alexander Kunz, Ulrike Gern, Anita Schmitt, Brigitte Neuber, Lei Wang, Angela Hückelhoven-Krauss, Birgit Michels, Susanne Hofmann, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Maria-Luisa Schubert
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss , Pp 448-454 (2020)
Chimeric antigen receptor (CAR) T cells are considered genetically modified organisms (GMOs) and constitute gene therapy medicinal products. Thus, CAR T cell manufacturing for clinical application is strictly regulated. Appropriate methods to assess
Externí odkaz:
https://doaj.org/article/552ff8d7e29d469aaee520f4a7c9305c
Autor:
Mingya Yang, Lei Wang, Ming Ni, Brigitte Neuber, Sanmei Wang, Wenjie Gong, Tim Sauer, Maria-Luisa Schubert, Angela Hückelhoven-Krauss, Ruixiang Xia, Jian Ge, Christian Kleist, Volker Eckstein, Leopold Sellner, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Chimeric antigen receptor T (CAR-T) cells targeting CD19 came into clinical practice for the treatment of B cell lymphoma in 2018. However, patients being treated for B cell lymphoma often suffer from comorbidities such as chronic pain, cardiovascula
Externí odkaz:
https://doaj.org/article/f57a21cfe3bc456a8a2d1f5faf832b86
Autor:
Mingya Yang, Lei Wang, Ming Ni, Brigitte Neuber, Sanmei Wang, Wenjie Gong, Tim Sauer, Leopold Sellner, Maria-Luisa Schubert, Angela Hückelhoven-Krauss, Jian Hong, Lixin Zhu, Christian Kleist, Volker Eckstein, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Chimeric antigen receptor (CAR) T cell therapy has shown promising responses in patients with refractory or relapsed aggressive B-cell malignancies that are resistant to conventional chemotherapy or stem cell transplantation. A potentially combinator
Externí odkaz:
https://doaj.org/article/d83a7e96c50a4d58b66c52230622c1bb
Autor:
Wenjie Gong, Lei Wang, Maria-Luisa Schubert, Christian Kleist, Brigitte Neuber, Sanmei Wang, Mingya Yang, Angela Hückelhoven-Krauss, Depei Wu, Anita Schmitt, Carsten Müller-Tidow, Hiroshi Shiku, Michael Schmitt, Leopold Sellner
Publikováno v:
Biomedicines, Vol 10, Iss 2, p 373 (2022)
Adoptive cell therapy with NY-ESO-1-specific T cells is a promising option for the treatment of soft tissue sarcoma (STS) but achieves only transient tumor control in the majority of cases. A strategy to optimize this cell therapeutic approach might
Externí odkaz:
https://doaj.org/article/6650dcceca714b109d1d13c489035f8e
Autor:
Avinoam Reichman, Alexander Kunz, Jara J. Joedicke, Uta E. Höpken, Anna Keib, Brigitte Neuber, David Sedloev, Lei Wang, Genqiao Jiang, Angela Hückelhoven-Krauss, Franziska Eberhardt, Carsten Müller-Tidow, Martin Wermke, Armin Rehm, Michael Schmitt, Anita Schmitt
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 2, p 903 (2022)
Chimeric-antigen-receptor (CAR)-T-cell therapy is already widely used to treat patients who are relapsed or refractory to chemotherapy, antibodies, or stem-cell transplantation. Multiple myeloma still constitutes an incurable disease. CAR-T-cell ther
Externí odkaz:
https://doaj.org/article/3db2c18fb74e4b93a9d4bd720be7894e